Skip to main content
SpringerLink
Log in

Biologikanebenwirkungen bei Psoriasis

Side effects of biologic therapies in psoriasis

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die Einführung der Biologika hat die Therapie der mittelschweren bis schweren Plaquepsoriasis bahnbrechend verändert. Indem die biologischen Therapien der Psoriasis kontinuierlich erweitert werden, ist es besonders wichtig, die Wirksamkeit und Sicherheit der Substanzen nicht nur in klinischen Studien, sondern auch in langfristigen Anwendungsbeobachtungen im Rahmen von Registern zu ermitteln.

Ziel der Arbeit

Es erfolgt die Darstellung typischer Nebenwirkungen und signifikanter Risiken der Biologikatherapien im Rahmen der Psoriasis unter der Berücksichtigung psoriatischer Kontrollpopulationen.

Material und Methoden

Es wurde eine selektive Literatursuche in PubMed durchgeführt, und Studien zur Langzeitsicherheit im Rahmen der Psoriasisregister PsoBest, PSOLAR und BADBIR wurden ausgewertet.

Ergebnisse und Diskussion

Zur Beurteilung der langfristigen Sicherheit der Biologika ist es von besonderer medizinischer Bedeutung, die Verläufe an möglichst vielen Patienten in Langzeitregistern zu beobachten. Eine Tendenz zu verbesserten Nebenwirkungs- und Sicherheitsprofilen der neueren biologischen Medikamente scheint sich abzuzeichnen.

Abstract

Background

The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies.

Aim

Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented.

Materials and methods

A selective literature search was conducted in PubMed and long-term safety studies of the psoriasis registries PsoBest, PSOLAR and BADBIR were evaluated.

Results and discussion

To assess the long-term safety of biologics, the evaluation of the course of large patient cohorts in long-term registries is of particular medical importance. Newer biologic drugs seem to exhibit a better safety profile than older ones.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Blauvelt A, Lebwohl MG, Bissonnette R (2015) IL-23/IL-17 A dysfunction phenotypes inform possible clinical effects from Anti-IL-17 A therapies. J Invest Dermatol 135:1946–1195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lockwood SJ, Prens LM, Kimball AB (2018) Adverse reactions to biologics in psoriasis. Curr Probl Dermatol 53:1–14

    Article  PubMed  Google Scholar 

  3. Papp KA, Strober B, Augustin M et al (2012) PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 11:1210–1217

    CAS  PubMed  Google Scholar 

  4. Iskandar IYK, Ashcroft DM, Warren RB et al (2017) Patterns of biologic therapy use in the management of psoriasis: Cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 176:1297–1307

    Article  CAS  PubMed  Google Scholar 

  5. Reich K, Mrowietz U, Radtke MA et al (2015) Drug safety of systemic treatments for psoriasis: Results from The German Psoriasis Registry PsoBest. Arch Dermatol Res 307:875–883

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Menter A, Feldman SR, Weinstein GD et al (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56(31):e1–e15

    Google Scholar 

  7. Gordon KB, Langley RG, Leonardi C et al (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55:598–606

    Article  PubMed  Google Scholar 

  8. Tyring S, Gordon KB, Poulin Y et al (2007) Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143:719–726

    Article  CAS  PubMed  Google Scholar 

  9. Kwon HJ, Coté TR, Cuffe MS et al (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807–811

    Article  PubMed  Google Scholar 

  10. Solomon DH, Rassen JA, Kuriya B et al (2013) Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 72:1813–1818

    Article  CAS  PubMed  Google Scholar 

  11. Hastings R, Ding T, Butt S et al (2010) Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (hoboken) 62:764–769

    Article  Google Scholar 

  12. Hsu L, Snodgrass BT, Armstrong AW (2014) Antidrug antibodies in psoriasis: A systematic review. Br J Dermatol 170:261–273

    Article  CAS  PubMed  Google Scholar 

  13. Leonardi CL, Kimball AB, Papp KA (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674

    Article  CAS  PubMed  Google Scholar 

  14. Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675–1684

    Article  CAS  PubMed  Google Scholar 

  15. Lebwohl M, Leonardi C, Griffiths CE et al (2012) Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 66:731–741

    Article  CAS  PubMed  Google Scholar 

  16. Gottlieb AB, Kalb RE, Langley RG et al (2014) Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 13:1441–1448

    CAS  PubMed  Google Scholar 

  17. Stamell EF, Kutner A, Viola K et al (2013) Ustekinumab associated with flares of psoriatic arthritis. Jama Dermatol 149:1410–1413

    Article  PubMed  Google Scholar 

  18. Leonardi C, Matheson R, Zachariae C et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190–1199

    Article  CAS  PubMed  Google Scholar 

  19. Saeki H, Nakagawa H, Ishii T et al (2015) Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29:1148–1155

    Article  CAS  PubMed  Google Scholar 

  20. van de Kerkhof PC, Griffiths CE, Reich K et al (2016) Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75:83–98

    Article  PubMed  Google Scholar 

  21. Griffiths CE, Reich K, Lebwohl M (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 386:541–551

    Article  CAS  PubMed  Google Scholar 

  22. Gordon KB, Blauvelt A, Papp KA et al (2016) Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375:345–356

    Article  CAS  PubMed  Google Scholar 

  23. Blauvelt A, Prinz JC, Gottlieb AB et al (2016) Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial. J Drugs Dermatol 15:1226–1234

    PubMed  Google Scholar 

  24. Crowley J, Thaçi D, Joly P et al (2017) Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 77:310–317

    Article  CAS  PubMed  Google Scholar 

  25. Reich K, Augustin M (2017) Arzneimittelsicherheit bei Psoriasis: Welche Rolle spielt Suizidalität? J Dtsch Dermatol Ges 15:353–355

    Article  PubMed  Google Scholar 

  26. Wollina U, Hansel G, Koch A et al (2008) Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9:1–14

    Article  PubMed  Google Scholar 

  27. Puig L (2018) Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 53:49–63

    Article  PubMed  Google Scholar 

  28. Seneschal J, Milpied B, Taieb A (2012) Cutaneous drug eruptions associated with the use of biologies and cutaneous drug eruptions mimicking specific skin diseases. Chem Immunol Allergy 97:203–216

    Article  PubMed  Google Scholar 

  29. Kalb RE, Fiorentino DF, Lebwohl MG (2015) Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the psoriasis longitudinal assessment and registry (PSOLAR). Jama Dermatol 151:961–969

    Article  PubMed  Google Scholar 

  30. Shalom G, Zisman D, Bitterman H et al (2015) Systemic therapy for psoriasis and the risk of herpes zoster: A 500,000 person-year study. Jama Dermatol 151:533–538

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane, Auenweg 38, 06847, Dessau-Roßlau, Deutschland

    A. Altenburg &  C. C. Zouboulis

  2. Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, CVderm, Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistr. 52, 20246, Hamburg, Deutschland

    M. Augustin

  3. MVZ des Städtischen Klinikums Dessau gGmbH, Luchstr. 19, 06862, Dessau-Roßlau, Deutschland

    A. Altenburg

Authors
  1. A. Altenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Augustin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. C. Zouboulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Altenburg.

Ethics declarations

Interessenkonflikt

A. Altenburg, M. Augustin und C.C. Zouboulis geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Altenburg, A., Augustin, M. & Zouboulis, C.C. Biologikanebenwirkungen bei Psoriasis. Hautarzt 69, 290–297 (2018). https://doi.org/10.1007/s00105-018-4156-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-018-4156-z

Schlüsselwörter

Keywords

Search

Navigation